Histological findings on jaw osteonecrosis associated with bisphosphonates (BONJ) or with radiotherapy (ORN) in humans

References

• Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839–47.
   PubMedGoogle Scholar
• Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone 2011;49:42–9.
   PubMed Web of Science ®Google Scholar
• Scheller EL, Baldwin CM, Kuo S, D'Silva NJ, Feinberg SE, Krebsbach PH, et al. Bisphosphonates inhibit expression of p63 by oral keratinocytes. J Dent Res 2011;90:894–9.
   PubMedGoogle Scholar
• Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate associated osteonecrosis of the jaw. A review. J Am Dent Assoc 2009;140:864–75.
   PubMed Web of Science ®Google Scholar
• Cheng A, Daly CG, Logan RM, Stein B, Goss AN. Alveolar bone and the bisphosphonates. Aust Dent J 2009;54(Suppl 1):S51–61.
   Google Scholar
• American Association of Oral and Maxillo-Facial Surgeons (AAOMS). Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw—2009 Update. Available online at www.aaoms.org/docs/position_papers/BONJ_update.pdf. Accessed on January 18 2013.
   Google Scholar
• Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567–75.
   PubMed Web of Science ®Google Scholar
• Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363–70.
   PubMed Web of Science ®Google Scholar
• Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397–410.
   PubMed Web of Science ®Google Scholar
• Biasotto M, Chiandussi S, Dore F, Rinaldi A, Rizzardi C, Cavalli F, et al. Clinical aspects and management of bisphosphonates-associated osteonecrosis of the jaws. Acta Odontol Scand 2006;64:348–54.
   PubMed Web of Science ®Google Scholar
• Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, et al. Non exposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010;123:1060–4.
   PubMed Web of Science ®Google Scholar
• Marx RE. ORN: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983;41:283–8.
   PubMed Web of Science ®Google Scholar
• Curi MM, Dib LL, Kowalski LP, Landman G, Mangini C. Opportunistic actinomycosis in ORN of the jaws in patients affected by head and neck cancer: incidence and clinical significance. Oral Oncol 2000;36:294–9.
   PubMed Web of Science ®Google Scholar
• Hansen T, Wagner W, Kirkpatrick CJ, Kunkel M. Infected ORN of the mandible: follow-up study suggests deterioration in outcome for patients with Actinomyces-positive bone biopsies. Int J Oral Maxillofac Surg 2006;35:1001–4.
   PubMed Web of Science ®Google Scholar
• Støre G, Eribe ER, Olsen I. DNA-DNA hybridization demonstrates multiple bacteria in ORN. Int J Oral Maxillofac Surg 2005;34:193–6.
   PubMed Web of Science ®Google Scholar
• Donath K, Breuner GA. A method for the study of undecalcified bones and teeth with attached soft tissue. J Oral Pathol 1982;11:318–25.
   PubMed Web of Science ®Google Scholar
• Favia G, Pilolli GP, Maiorano E. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 2009;45:406–13.
   PubMedGoogle Scholar
• Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst 2011;103:232–40.
   PubMed Web of Science ®Google Scholar
• Hansen T, Kunkel M, Weber A, Kirkpatrick CJ. Osteonecrosis of the jaws in patients treated with bisphosphonates – histomorphologic analysis in comparison with infected ORN. J Oral Pathol Med 2006;35:155–60.
   PubMed Web of Science ®Google Scholar
• Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 2005;71:11–13.
   Google Scholar
• Ruggiero SL, Mehrotra B, Rosenberg T, Enhgroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527–34.
   PubMed Web of Science ®Google Scholar
• Lugassy G, Shaham R, Nemets A, Ben-Dor D, Nahlieli O. Severe osteiomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity. Am J Med 2004;117:440–1.
   PubMed Web of Science ®Google Scholar
• Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, et al. Actinomycosis of the jaws–histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected ORN. Virchows Arch 2007;451:1009–17.
   PubMedGoogle Scholar
• Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 2007;4:711–21.
   PubMedGoogle Scholar
• Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008;66:767–75.
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009;360:53–62.
   PubMed Web of Science ®Google Scholar
• Thiel HJ. The ORN: Part I. Etiology, pathogenesis, clinic, and risk factors. Radiobiol Radiother 1989;30:397–413.
   PubMedGoogle Scholar
• Andrews N, Griffiths C. Dental complications of head and neck radiotherapy: Part 1. Aust Dent J 2001;46:88–94.
   PubMed Web of Science ®Google Scholar
• Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthesis pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001;59:193–202.
   PubMed Web of Science ®Google Scholar
• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–18.
   PubMed Web of Science ®Google Scholar
• Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538–44.
   PubMed Web of Science ®Google Scholar
• Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2002;8:1080–4.
   PubMed Web of Science ®Google Scholar
• Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66:987–94.
   PubMed Web of Science ®Google Scholar